Regulatory Approvals

FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC

By

Regulatory Approvals — FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC  Urology Times

Read the original at Regulatory Approvals ↗

Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. July 31, 2026.

By

Related Post

Regulatory Approvals

FDA Approval Insights: Subcutaneous Isatuximab Via an On-Body Delivery System Represents a “Game-Changer” in Multiple Myeloma: With Douglas W. Sborov, MD, MS

Regulatory Approvals

FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI in mAPMN/S Prostate Cancer

Regulatory Approvals

FDA clears autoinjector drug for home treatment of heart failure edema

Financial News For All

Mergers & Acquisitions

PFL-MVP merger creates new MMA challenger with eye on 2027 launch

Labor

‘Largest strike’ in cannabis history ends at Illinois MSO

Labor

V&A Storehouse Workers Vote to Strike Over “Amazon-Style” Conditions

Labor

Kaiser used an algorithm — not clinicians — to triage mental health patients, a union alleges